Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences

PLoS Pathogens

Volumn 12, Issue 2, 2016, Pages

  Tartaglia, Lawrence J ^a   Chang, Hui Wen ^a   Lee, Benjamin C ^a   Abbink, Peter ^a   Ng’ang’a, David ^a   Boyd, Michael ^a   Lavine, Christy L ^a   Lim, So Yon ^a   Sanisetty, Srisowmya ^a   Whitney, James B ^a,b   Seaman, Michael S ^a,b   Rolland, Morgane ^c   Tovanabutra, Sodsai ^c   Ananworanich, Jintanat ^c   Robb, Merlin L ^c   Kim, Jerome H ^c,d   Michael, Nelson L ^c   Barouch, Dan H ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING RECOMBINANT FORM 01 AE ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ADULT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SEQUENCE ANALYSIS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; CELL CULTURE; GENETICS; IMMUNOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; MACACA MULATTA; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA;

EID: 84959542425     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005431     Document Type: Article

References (22)

1. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol. 2001;75: 1990–1995. 11160699
2. Lu Y, Salvato MS, Pauza CD, Li J, Sodroski J, Manson K, et al. Utility of SHIV for testing HIV-1 vaccine candidates in macaques. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12: 99–106. 8680896
3. Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, et al. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS ONE. 2010;5: e11689. doi: 10.1371/journal.pone.001168920657739
4. Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, et al. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways. J Virol. 2010;84: 9995–10003. doi: 10.1128/JVI.00505-1020660190
5. Kijak GH, Tovanabutra S, Rerks-Ngarm S, Nitayaphan S, Eamsila C, Kunasol P, et al. Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial. J Virol. 2013;87: 7265–7281. doi: 10.1128/JVI.03070-1223576510
6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361: 2209–2220. doi: 10.1056/NEJMoa090849219843557
7. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366: 1275–1286. doi: 10.1056/NEJMoa111342522475592
8. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, Hertz T, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490: 417–420. doi: 10.1038/nature1151922960785
9. Parker ZF, Iyer SS, Wilen CB, Parrish NF, Chikere KC, Lee F-H, et al. Transmitted/Founder and Chronic HIV-1 Envelope Proteins Are Distinguished by Differential Utilization of CCR5. J Virol. 2013;87: 2401–2411. doi: 10.1128/JVI.02964-1223269796
10. Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA. 2013;110: 6626–6633. doi: 10.1073/pnas.130428811023542380
11. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105: 7552–7557. doi: 10.1073/pnas.080220310518490657
12. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512: 74–77doi: 10.1038/nature1359425042999
13. Ananworanich J, Schuetz A, Vandergeeten C, Sereti I, de Souza M, Rerknimitr R, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE. 2012;7: e33948. doi: 10.1371/journal.pone.003394822479485
14. Chang H-W, Tartaglia LJ, Whitney JB, Lim S-Y, Sanisetty S, Lavine CL, et al. Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J Virol. 2015;89: 1965–1974. doi: 10.1128/JVI.03279-1425473043
15. Montefiori DC, Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol. 2009;485: 395–405. doi: 10.1007/978-1-59745-170-3_2619020839
16. Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin C-L, Bilska M, Greene KM, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409: 131–146. doi: 10.1016/j.jim.2013.11.02224291345
17. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003;41: 4531–4536. 14532178
18. Liao H-X, Bonsignori M, Alam SM, McLellan JS, Tomaras GD, Moody MA, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38: 176–186. doi: 10.1016/j.immuni.2012.11.01123313589
19. Etemad-Moghadam B, Sun Y, Nicholson EK, Fernandes M, Liou K, Gomila R, et al. Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol. 2000;74: 4433–4440. 10756060
20. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH, Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol. 1995;69: 39–48. 7983734
21. Nolen TL, Hudgens MG, Senb PK, Koch GG, Analysis of repeated low-dose challenge studies. Stat Med. 2015;34: 1981–1992doi: 10.1002/sim.646225752266
22. Barouch DH, Stephenson KE, Borducchi EN, Smith K, Stanley K, McNally AG, et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell. 2013;155: 531–539. doi: 10.1016/j.cell.2013.09.06124243013